AbbVie today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback